Huadong Medicine Co., Ltd. (000963)

Equity Research Report　|　Industry: Integrated Pharmaceutical Group　|　Report Date: September 13, 2026　|　As of the September 11, 2026 close; shareholder and institutional holding data as of June 30, 2026, subject to a quarterly lag.

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Executive Summary

Huadong Medicine recorded revenue of RMB 22.067 billion in the first half of 2026, up 1.81% year on year, and net profit attributable to shareholders of RMB 1.861 billion, up 2.53% year on year. Non-recurring net profit attributable to shareholders increased 5.44% year on year. However, second-quarter revenue of RMB 10.883 billion and net profit attributable to shareholders of RMB 859 million declined 0.51% and 4.62%, respectively, year on year, indicating some moderation in growth momentum. By business segment, Sino-American Huadong generated revenue of RMB 7.969 billion and net profit attributable to shareholders of RMB 1.740 billion, up 8.92% and 10.12%, respectively; pharmaceutical distribution generated revenue of RMB 14.182 billion and net profit of RMB 233 million, maintaining modest growth; industrial microbiology revenue increased 18.64%, while the medical aesthetics segment generated revenue of RMB 651 million, down 41.43% year on year, and remained the primary drag on current results.

The company’s business structure is characterized by “pharmaceutical manufacturing contributing profits, pharmaceutical distribution providing scale and cash flow, and medical aesthetics and industrial microbiology seeking second growth curves.” In 2025, pharmaceutical manufacturing revenue was RMB 14.784 billion, up 7.04% year on year; pharmaceutical distribution revenue was RMB 28.697 billion, up 5.92%; and medical aesthetics revenue was RMB 1.826 billion, down 21.50%. The company’s gross margin declined from 33.21% in 2024 to 32.36% in 2025, while net profit attributable to shareholders fell from RMB 3.512 billion to RMB 3.414 billion. The decline in medical aesthetics, losses at overseas associates, goodwill impairment related to UK-based Sinclair, and the relatively high contribution from distribution jointly weighed on profitability.

The company continues to advance its innovation and product pipeline: HDM2005 received U.S. FDA Fast Track designation, HDP-101/HDM2027 received Chinese clinical-trial approval, and MaiLi Precise obtained domestic marketing approval, with progress also made toward overseas MDR CE certification. However, these developments do not equate to commercial launch or realized profits. In the 12th round of national centralized volume-based procurement, three products were selected and four were not selected. The products not selected generated combined sales of approximately RMB 4.634 billion in 2025, equivalent to approximately 10.62% of the company’s full-year revenue. Changes in their hospital-market share warrant attention. Based on the closing price of RMB 26.26 on September 11, 2026, the company’s forward P/E was approximately 13.3–13.7x. The share price was below major moving averages and close to its 52-week low; technical indicators were weak and accompanied by oversold conditions.

2. Company Overview

2.1 Basic Information

2.2 Core Businesses and Product Portfolio

• Pharmaceutical manufacturing: Focuses on specialty, chronic-disease and special-use medicines, covering chronic kidney disease, immunology, oncology, endocrinology, digestive diseases and cardiovascular diseases. The company prioritizes oncology, endocrinology and autoimmune diseases. Revenue was RMB 14.784 billion in 2025, up 7.04% year on year, making this the company’s core profit source.
• Pharmaceutical distribution: Distributes pharmaceuticals, medical devices and medicinal materials and decoction pieces, while expanding into cold-chain logistics, vaccines, specialty-drug logistics, CSO, SPD, pharmaceutical e-commerce and integrated pharmaceutical services. Revenue was RMB 28.697 billion in 2025, up 5.92% year on year. The segment primarily provides scale, channels, cash flow and supply-chain synergies.
• Medical aesthetics: Covers regenerative fillers, hyaluronic acid, botulinum toxin, facial-lifting threads and energy-based devices. Major brands include Ellansé, MaiLi, Glacial, Reaction and Préime. Revenue was RMB 1.826 billion in 2025, down 21.50% year on year.
• Industrial microbiology: Focuses on four areas: xRNA raw materials, specialty APIs and intermediates, healthcare and biomaterials, and animal health. Sales revenue was RMB 777 million in 2025, up 9.34% year on year. Although currently small in scale, the segment has value as a platform for R&D, pilot testing and commercial production.

2.3 Position in the Upstream and Downstream Value Chain and Cost-Profit Structure

Huadong Medicine occupies an integrated position in the middle and downstream portions of the pharmaceutical value chain, covering pharmaceutical R&D, manufacturing, distribution, medical-aesthetics products and biomanufacturing. Pharmaceutical manufacturing is the main profit engine, pharmaceutical distribution is the foundation for scale, channels and cash flow, and medical aesthetics and industrial microbiology represent potential second growth curves.

• Pharmaceutical manufacturing procures APIs, drug intermediates, excipients, packaging materials, culture media and other production materials. Biologics, ADCs, peptides and GLP-1 products also require antibodies, linkers, toxins, peptide raw materials and related production equipment.
• The medical-aesthetics business procures regenerative materials, hyaluronic acid, botulinum toxin, energy-based devices and overseas branded products. Pharmaceutical distribution procures pharmaceuticals, medical devices, medicinal materials and decoction pieces, and other pharmaceutical products.
• Purchases from the five largest suppliers in 2025 totaled RMB 5.317 billion, accounting for 18.02% of total annual procurement. The largest supplier accounted for 6.45%, while related-party purchases among the five largest suppliers accounted for 0%. Overall supplier concentration was not high. The data are from the annual report, but suppliers were disclosed anonymously as “Supplier B6” and similar labels, making it impossible to identify specific suppliers or product categories.
• The annual report did not disclose procurement amounts or unit prices by category, such as APIs, intermediates, excipients, packaging materials or medical-aesthetics materials. It is therefore impossible to accurately determine the impact of any single raw material on overall costs. Bargaining power on the pharmaceutical-distribution procurement side is relatively limited. Generic drugs and APIs are affected by centralized procurement, homogenized competition and raw-material price fluctuations. Innovative drugs, proprietary drugs and medical-aesthetics products with patent or registration barriers generally have relatively stronger pricing power, but remain subject to reimbursement negotiations, hospital access, channel rebates and industry competition.
• Downstream customers of pharmaceutical manufacturing mainly include tertiary hospitals, secondary hospitals, primary healthcare institutions, retail pharmacies, specialty pharmacies and overseas pharmaceutical markets. Pharmaceutical-distribution customers include medical institutions, retail institutions, pharmacies, pharmaceutical manufacturers and patient-service terminals. Medical-aesthetics customers mainly include medical-aesthetics departments of public hospitals, private medical-aesthetics institutions and physician-training systems. Industrial-microbiology customers include domestic and overseas pharmaceutical companies, CDMO companies, in-vitro diagnostic companies, health-product companies, medical-aesthetics companies and animal-health customers.
• Sales to the five largest customers in 2025 totaled RMB 9.891 billion, accounting for 22.68% of total annual sales. The largest customer accounted for 8.84%, while related-party sales among the five largest customers accounted for 0%. This was based on the consolidated group scope for 2025. Customer names were disclosed anonymously as “Customer A1,” “Customer A2” and similar labels, making it impossible to identify specific end industries. Accordingly, the figure cannot be directly equated with customer concentration in pharmaceutical manufacturing. The research notes did not provide other annual data for cross-checking.
• Bargaining relationships in the downstream pharmaceutical-manufacturing market are differentiated. Innovative drugs face reimbursement negotiations and access requirements to enter reimbursement and hospital formularies. Generic drugs face price cuts under centralized procurement and competition from the same products. Pharmaceutical distribution is affected by hospital collection cycles, terminal cost controls and margin compression across distribution links. Medical-aesthetics products are affected by bargaining with institutional channels, physician training, terminal pricing systems and industry competition.
• The company is not a price taker for a single commodity as a whole. Pharmaceutical distribution and mature generic drugs are more subject to market prices and competitive constraints, while innovative drugs, proprietary drugs and medical-aesthetics products with registration or brand barriers have relatively stronger pricing power. However, the company has not disclosed complete information on sales discounts, hospital credit periods or customer contract terms. These conclusions are inferences based on the business structure.
• As of December 31, 2025, the book balance of accounts receivable was RMB 9.519 billion and the carrying value was RMB 8.986 billion. The book balance of accounts receivable represented approximately 21.83% of 2025 revenue and approximately 2.79x 2025 net profit attributable to shareholders. Of year-end accounts receivable, RMB 8.918 billion was due within one year, accounting for approximately 93.70%; RMB 477 million was due within one to two years, RMB 87 million within two to three years, and RMB 37 million after more than three years. Provisions for bad debts totaled RMB 533 million, representing an aggregate provision ratio of 5.60%. Accounts receivable mainly reflect working-capital occupation arising from the scale of pharmaceutical distribution and settlement cycles with hospitals and channel customers. However, the annual report did not break down receivables among pharmaceutical manufacturing, pharmaceutical distribution, medical aesthetics and industrial microbiology, making it impossible to assess collection quality by segment.
• Supplier-concentration data are for 2025: purchases from the five largest suppliers accounted for 18.02% of total annual procurement, and the largest supplier accounted for 6.45%. Customer-concentration data are for 2025: sales to the five largest customers accounted for 22.68% of total annual sales, and the largest customer accounted for 8.84%. Both sets of data are from the annual report, but suppliers and customers were disclosed anonymously, preventing identification of the specific parties or business segments. The research notes did not provide other annual concentration data for cross-checking. The latest annual report should be consulted for definitive information.

Huadong Medicine is positioned in the middle and downstream portions of the pharmaceutical value chain. Pharmaceutical manufacturing extends into innovative-drug R&D, APIs, formulations and commercial production, with certain R&D and registration barriers. Pharmaceutical distribution operates in pharmaceutical circulation and supply-chain services, with large revenue scale but relatively low margins. Medical aesthetics sits between product R&D, brand operations and institutional channels. Industrial microbiology operates in the biomanufacturing and specialty-raw-material supply chain. Profit improvement will depend mainly on the volume ramp-up of innovative drugs, a higher contribution from pharmaceutical manufacturing, product-mix upgrades, improved distribution turnover efficiency and the commercialization of ADCs, peptides, GLP-1, xRNA and new medical-aesthetics products, rather than simply expanding distribution revenue.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

Non-recurring net profit attributable to shareholders was RMB 1.858 billion in the first half of 2026, up 5.44% year on year; basic EPS was RMB 1.061; net cash flow from operating activities was RMB 2.499 billion, up approximately 1.7% year on year. Non-recurring net profit attributable to shareholders was RMB 868 million in the second quarter of 2026, up 0.40% year on year. Full-year 2025 non-recurring net profit attributable to shareholders was RMB 3.311 billion, down 1.20% year on year.

The company maintained modest growth in revenue and net profit attributable to shareholders in the first half of 2026, but both revenue and attributable net profit weakened year on year in the second quarter, mainly due to continued pressure on the medical-aesthetics business. By segment, Sino-American Huadong generated revenue of RMB 7.969 billion in the first half of 2026, up 8.92% year on year, and net profit attributable to shareholders of RMB 1.740 billion, up 10.12%. Pharmaceutical distribution generated revenue of RMB 14.182 billion, up 1.68%, and net profit of RMB 233 million, up 3.02%. Industrial microbiology sales revenue was RMB 437 million, up 18.64%. Medical-aesthetics revenue after elimination of internal offsets was RMB 651 million, down 41.43% year on year.

3.2 Earnings Forecasts

As of September 10, 2026, the earnings-forecast page of Tonghuashun showed that 16 institutions had issued forecasts for 2026 results during the preceding six months. The revenue forecast sample mainly covered 13 institutions, and the number of institutions was not fully consistent across net profit and EPS forecasts. These data are aggregated forecasts from institutional research reports, not company guidance or audited figures. Institutional forecasts for net profit attributable to shareholders were approximately RMB 3.427–4.261 billion for 2026, RMB 3.057–4.722 billion for 2027 and RMB 3.560–4.863 billion for 2028.

3.3 Valuation and Institutional Ratings

As of September 10, 2026, the share price was approximately RMB 26.62 and total market capitalization was approximately RMB 46.684 billion. LiXinger disclosed static/rolling PE-TTM of approximately 13.49x and PB of approximately 1.83x. Based on the institutional average EPS forecasts, forward P/E for 2026–2028 was approximately 12.4x, 11.5x and 10.4x, respectively. Based on full-year 2025 attributable net profit of RMB 3.414 billion, first-half 2025 attributable net profit of RMB 1.815 billion and first-half 2026 attributable net profit of RMB 1.861 billion, attributable net profit for the latest 12 months is estimated at approximately RMB 3.460 billion, implying an estimated PE-TTM of approximately 13.5x. This is an estimate based on publicly disclosed financial reports rather than a figure directly disclosed by the company. Current valuation already reflects some of the decline in medical aesthetics and the pressure from centralized procurement. Overall, the company is not highly valued, but the scope for valuation recovery depends on a recovery in medical aesthetics, absorption of the impact from the 12th round of centralized procurement, commercialization of innovative drugs, overseas medical-aesthetics operations and risks related to Sinclair. Institutional earnings expectations vary considerably. In particular, China Galaxy forecasts 2027 attributable net profit of RMB 3.057 billion, compared with China Merchants Securities’ forecast of RMB 4.096 billion.

4. Recent News and Announcements

4.1 Semiannual Cash-Dividend Implementation Announcement

On September 11, 2026, Huadong Medicine disclosed the Announcement on the Implementation of the 2026 Semiannual Profit Distribution. Based on total share capital of 1,753,736,848 shares, the company will distribute a cash dividend of RMB 3.50 per 10 shares, including tax, to all shareholders. No bonus shares will be issued and no capitalization of capital reserves will be carried out. Total cash dividends are expected to be RMB 613,807,896.80. The record date is September 17, 2026, while the ex-dividend date and cash-dividend payment date are both September 18, 2026. The distribution plan was authorized at the 2025 Annual General Meeting held on May 20, 2026, and approved by the board on August 25, 2026, without requiring resubmission to the shareholders’ meeting. This is a cash dividend, not a share repurchase. Sources: full announcements on Sina Finance and the individual-stock calendar on East Money.

4.2 HDM2005 Receives U.S. FDA Fast Track Designation

On August 26, 2026, Hangzhou Sino-American Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of Huadong Medicine, received a certification letter from the U.S. FDA. The company’s internally developed innovative drug HDM2005 for injection received FDA Fast Track designation. The indication is relapsed/refractory mantle cell lymphoma after at least two lines of systemic therapy, including treatment with a BTK inhibitor. According to the company’s announcement, HDM2005 is the first domestically developed investigational ROR1-targeting ADC to receive FDA Fast Track designation and is also Huadong Medicine’s first independently developed ADC project. The product remains in clinical development. Fast Track designation does not mean that the product has been approved for marketing or has generated commercial revenue. Sources: company announcements on China Financial Information Network and related reports from China Securities Journal.

4.3 HDP-101/HDM2027 Receives Chinese Clinical-Trial Approval

On August 26, 2026, the company disclosed that a wholly owned subsidiary had obtained a Drug Clinical Trial Approval Notice. The approved project is the combination-therapy clinical trial of HDP-101/HDM2027, with the international nonproprietary name pamlectabart tismanitin. It is being jointly developed by Sino-American Huadong and Heidelberg Pharma AG, the company’s German associate. This is a clinical-trial approval, not a marketing approval. The product must still undergo clinical studies, a marketing application and regulatory review and approval. Sources: Sina Finance announcement listings and announcement portal, and related disclosures from Shanghai Securities Journal.

4.4 Domestic Registration and EU MDR CE-Certification Progress for Medical-Aesthetics Products

On August 26, 2026, the company disclosed that a wholly owned subsidiary had obtained a medical-device registration certificate. The announcement concerned domestic marketing approval for the medical-aesthetics product MaiLi Precise. The company stated that the approval would not have a material impact on its current financial position or operating results, but could have a certain positive effect on future performance. Product sales will be affected by industry policies, market demand and competition, and future profit contribution remains uncertain. On August 10, 2026, the company also disclosed that a wholly owned medical-device subsidiary had obtained EU MDR CE certification, while clearly stating that the product had not yet obtained a domestic medical-device registration certificate and had not generated actual sales revenue at that time. Sources: Shanghai Securities Journal announcements, Shenzhen Stock Exchange announcement PDFs and the Sina Finance company-announcement list.

4.5 Selected and Non-Selected Products in the 12th Round of National Centralized Volume-Based Procurement

On August 3, 2026, the company disclosed the tentative selection results for its participation in the 12th round of national centralized volume-based procurement. Selected products included cyclosporine soft capsules, tacrolimus capsules and mesalazine enteric-coated tablets. Their combined sales revenue in 2025 was approximately RMB 2.076 billion, accounting for approximately 4.76% of the company’s 2025 revenue. Combined sales revenue in the first quarter of 2026 was approximately RMB 533 million, accounting for approximately 4.76% of revenue for the period. Products not selected included isavuconazole injection, pioglitazone hydrochloride and metformin hydrochloride tablets, indobufen tablets and benzoic acid alogliptin tablets. Their combined sales revenue in 2025 was approximately RMB 4.634 billion, accounting for approximately 10.62% of the company’s 2025 revenue. Combined sales revenue in the first quarter of 2026 was approximately RMB 1.348 billion, accounting for approximately 12.05% of revenue for the period. The company stated that prices for the selected products would be lower than their original prices, but that selection would help consolidate their hospital-market base. Products not selected could face the temporary loss of contracted procurement volumes at public medical institutions and pressure from declining hospital-market share. As of the announcement date, the relevant procurement agreements had not been signed, and the final execution and impact on results remained uncertain. Sources: full announcement on Sina Finance, China Food and Drug News and China Financial Information Network.

4.6 Pledge and Release of Pledged Shares by the Controlling Shareholder

On July 2, 2026, the company disclosed the pledge and release of pledged shares by its controlling shareholder, China Grand Enterprises Group Co., Ltd. China Grand Enterprises released pledges over 16.33 million shares on June 30, 2026, and newly pledged 22.50 million shares on June 29, 2026. As of August 25, 2026, China Grand Enterprises had pledged an aggregate of 144,810,000 company shares, equivalent to approximately 8.26% of total share capital, with no share freezes. Data from East Money and Tonghuashun showed that as of September 11, 2026, the total number of pledged shares remained approximately 145 million, representing approximately 8.26%, with no significant further change in September. Recent activity mainly involved pledge refinancing and partial release-and-repledge arrangements, rather than an announcement of a reduction by the controlling shareholder. Sources: pledge announcement on Sina Finance, Huadong Medicine’s 2026 semiannual report and the East Money individual-stock calendar.

4.7 Search Results for Repurchases, Shareholder Transactions, M&A and Restructuring, and Earnings Guidance

As of September 13, 2026, among the company announcements retrieved for July through September 2026, no new large-scale share-repurchase plan, repurchase implementation update or repurchase cancellation announcement by Huadong Medicine was identified. The company’s main recent shareholder-return measure was the cash dividend. No new announcement of a reduction plan by the controlling shareholder or major shareholders in September 2026 was identified. No major merger, acquisition, restructuring or change-of-control announcement from July through September 2026 was identified. Matters related to Heidelberg Pharma constitute clinical progress on an existing cooperation project and do not represent a major new acquisition during the period. As of September 13, 2026, no new earnings guidance for the first three quarters or full year of 2026 was identified. The report disclosed on August 27, 2026 was the semiannual report, a formal periodic report rather than earnings guidance.

4.8 Overall Assessment of Recent News and Uncertainty

As of September 13, 2026, recent news concerning Huadong Medicine includes a cash dividend of RMB 3.50 per 10 shares for the first half of 2026, totaling approximately RMB 614 million; FDA Fast Track designation for HDM2005; Chinese clinical-trial approval for HDP-101/HDM2027; domestic registration and overseas MDR CE-certification progress for medical-aesthetics products; three selected and four non-selected products in the 12th round of national centralized volume-based procurement; and approximately 144.81 million shares pledged by the controlling shareholder, representing 8.26% of total share capital. No new large-scale repurchase, major-shareholder reduction, major acquisition or penalty announcement has been identified to date. Most of the innovative-drug, medical-device and centralized-procurement matters remain at the designation, clinical, registration or tentative-selection stage. Positive implications in the announcements do not equate to realized revenue or profits. Final procurement agreements, actual execution volumes and the conversion of non-selected products to out-of-hospital markets may cause actual results to differ from the static estimates disclosed in the announcements.

5. Share-Price Performance and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

Huadong Medicine’s share price retreated rapidly after a high-volume surge on August 20, 2026, and closed at RMB 26.26 on September 11, close to the 52-week low of RMB 25.63 and the estimated Bollinger lower band of RMB 25.87. The closing price was below the Investing-based MA5, MA10, MA20 and longer-term moving averages. MACD was negative and RSI(14) was approximately 17.51, indicating simultaneous short- and medium-term weakness and oversold conditions. Oversold conditions support the possibility of a short-term technical rebound, but no trend reversal has been confirmed. Recent turnover rates were mainly in the 0.5%–0.9% range, with turnover value generally around RMB 240–400 million. Main-fund flows were generally negative, indicating insufficient support from incremental capital. As of June 30, 2026, the ten largest tradable shareholders collectively held approximately 67.15%, while institutional investors held approximately 70.22%. However, the number of shareholders increased 18.85% from March 31, 2026, and institutional holdings declined from the end of 2025. High concentration and periodic institutional position reductions can coexist.

5.3 Short-Term Outlook (Next Week; Scenario Analysis for Reference Only)

⚠️ Risk warning: The following content is a subjective scenario analysis based on the closing data, historical prices and technical indicators as of September 11, 2026. It does not constitute investment advice or a guarantee of future share-price performance.

① Key Technical Levels

② Scenarios for the Next Week (Subjective Weights, Not Statistical Probabilities)

• Low-level consolidation (relatively high subjective heuristic weight, approximately 50%–60%; not a statistical probability): Reference range of RMB 25.9–27.0. Conditions include holding around RMB 26.0, turnover value remaining within the recent normal range of approximately RMB 240–400 million, a clear narrowing of main-fund outflows, and no new systemic decline in the pharmaceutical sector. This scenario represents weak consolidation following oversold conditions and does not yet constitute a trend reversal
• Continued weakness (medium subjective heuristic weight, approximately 30%; not a statistical probability): Reference range of RMB 25.6–26.1, with downside-break risk below RMB 25.6 in an extreme case. Conditions include a closing price below RMB 26.0, continued net outflows from main funds, turnover value materially above recent norms with the close near the intraday low, or continued weakness in the pharmaceutical sector and broader market risk appetite. If the RMB 25.6–25.9 area is broken on high volume, the effectiveness of support near the 52-week low may weaken
• Strengthening rebound (low subjective heuristic weight, approximately 10%–20%; not a statistical probability): Reference range of RMB 26.9–27.6. Conditions include recovering RMB 26.9–27.0, then holding above RMB 27.4, daily turnover value rising above approximately RMB 400 million and remaining there for at least two days, a shift from continued net outflows to clear net inflows by main funds, and a simultaneous rebound in the pharmaceutical sector. If RMB 27.4 is recovered on high volume, the RMB 27.8–28.3 area may be observed. Before volume and fund flows confirm the move, a one-day rebound should not be directly regarded as a trend reversal

③ Fund-Flow and Liquidity Background

As of September 11, 2026, the daily turnover rate was 0.58%, while recent turnover rates were mostly in the 0.5%–0.9% range. Turnover value over the past several trading days was approximately RMB 240–400 million, while event-driven trading days such as August 20 and August 21 saw turnover value expand to approximately RMB 1.5–2.0 billion. Shareholder data are as of June 30, 2026. The ten largest tradable shareholders collectively held approximately 67.15%, and institutional investors held approximately 70.22%, including funds, insurance companies, the National Social Security Fund and ETFs. However, these data are subject to a quarterly lag and may differ from the actual structure on September 11, 2026. The number of shareholders increased 18.85% from March 31, 2026, while institutional holdings declined from the end of 2025, indicating that high concentration and periodic institutional position reductions coexisted. In practice, the low-turnover environment indicates that there was no obvious large-scale exchange of positions during the recent decline, but it also reflects insufficient support from incremental capital. High concentration among the ten largest shareholders alone cannot demonstrate strong short-term price support.

Observable volume-confirmation signals: If daily turnover value exceeds approximately RMB 400 million for two consecutive days, while the closing price returns above RMB 27.0 and main-fund flows turn net positive, this may serve as a signal that short-term capital support is improving. If turnover expands but the share price continues to close lower, attention should be paid to high-volume distribution or panic selling.

④ Points to Monitor (Observation Framework Only, Not Trading Instructions)

• Observe whether the RMB 26.0–26.3 area can stabilize on lower volume; this is an observation framework, not a trading instruction.
• Observe whether the RMB 25.6–25.9 area experiences a high-volume breakdown, with particular attention to the validity of the RMB 25.63 52-week low; this is an observation framework, not a trading instruction.
• Observe whether the share price can regain the RMB 26.9–27.4 moving-average and prior high-volume trading area; this is an observation framework, not a trading instruction.
• Observe whether turnover value exceeds approximately RMB 400 million for two consecutive days and is accompanied by a shift to net inflows from main funds; this is an observation framework, not a trading instruction.

The above scenario analysis is based on the September 11, 2026 closing data and calculations using historical prices and technical indicators. Short-term share prices may also be affected by news, fund flows, broader market conditions and other factors. Technical indicators have inherent lags and limitations. This does not guarantee actual future performance or constitute a buy or sell recommendation. Investors should independently assess the latest market information and bear their own investment risks.

6. Industry Structure and Competitor Analysis

6.1 Industry Conditions

In 2025, China’s pharmaceutical industry was in a structural transition characterized by “pressure on generic drugs, accelerated innovation and rising industry concentration.” Reimbursement reform, volume-based procurement, healthcare anti-corruption measures and compliance regulation continued to advance. Prices and profit margins for traditional generic drugs were compressed, while innovative drugs, biosimilars, high-end medical devices, specialty traditional Chinese medicines and international products became new growth directions. According to Huadong Medicine’s annual report, revenue of China’s above-scale pharmaceutical manufacturing industry declined 1.2% year on year in 2025, while total profits reached RMB 349 billion. The industry displayed pressure on revenue, profit recovery and structural upgrading.

6.2 Competitive Landscape

• Innovation and R&D competition: R&D investment is high and clinical cycles are long in oncology, ADCs, CAR-T, GLP-1 and autoimmune diseases. R&D platforms, financial strength and commercialization capabilities are important barriers.
• Reimbursement and hospital-access competition: After approval, products still need access to reimbursement formularies, hospital formularies and various terminals. Commercialization capabilities are as important as R&D capabilities.
• Centralized procurement and cost-control competition: Mature generic drugs face price cuts under centralized procurement and homogenized competition. Companies need scale production, API integration and manufacturing efficiency to maintain profitability.
• Pharmaceutical-distribution network competition: The focus has shifted from expanding revenue scale to hospital coverage, specialty pharmacies, SPD, cold-chain logistics, specialty-drug services and accounts-receivable turnover efficiency.
• Medical-aesthetics product and channel competition: Product registration, materials technology, brands, physician education, institutional coverage and terminal pricing systems jointly determine competitiveness. China’s domestic medical-aesthetics market continues to face strong channel and pricing competition.

6.3 Major Competitors

Because Huadong Medicine is diversified, no single comparable company fully covers all of its businesses. Hengrui Medicine is suitable for comparison in innovative-drug R&D and commercialization, Kelun Pharmaceutical in manufacturing, ADCs, APIs and biomanufacturing, Shanghai Pharmaceuticals in pharmaceutical distribution and supply chains, and Imeik and Bloomage Biotech in medical-aesthetics materials and products. Huadong Medicine’s integrated profile consists of high-margin pharmaceutical manufacturing, low-margin pharmaceutical distribution, medical aesthetics and industrial microbiology operating across multiple segments.

7. Risk Factors

• Risk of continued decline in medical aesthetics: Medical-aesthetics revenue declined 41.43% year on year in the first half of 2026 and 21.50% for full-year 2025. Although MaiLi Precise received domestic marketing approval, the company disclosed that it would not have a material impact on current financial position or operating results. Future sales and profit contribution remain uncertain.
• Risk of hospital-market loss due to non-selection in centralized procurement: In the 12th round of national centralized volume-based procurement, isavuconazole injection, pioglitazone hydrochloride and metformin hydrochloride tablets, indobufen tablets and benzoic acid alogliptin tablets were not selected. Their combined sales revenue in 2025 was approximately RMB 4.634 billion, accounting for approximately 10.62% of full-year revenue. They may face temporary losses of contracted procurement volumes at public medical institutions and declining hospital-market share.
• Risk that centralized-procurement price cuts compress profits: Cyclosporine soft capsules, tacrolimus capsules and mesalazine enteric-coated tablets were selected, but the company disclosed that their selected prices would be lower than the original prices. These products generated combined sales of approximately RMB 2.076 billion in 2025. The actual impact of final procurement agreements, execution volumes and prices on profits remains uncertain.
• Uncertainty in innovative-drug R&D and commercialization: HDM2005 has only received U.S. FDA Fast Track designation, while HDP-101/HDM2027 has only received clinical-trial approval. Neither indicates marketing approval or commercial revenue. The products still face uncertainties relating to clinical development, marketing applications, regulatory review and approval, and market access.
• Overseas medical-aesthetics and goodwill-impairment risk: Goodwill impairment related to UK-based Sinclair and losses at overseas associates pressured profits in 2025. If the recovery of overseas medical-aesthetics operations falls short of expectations, profitability and asset quality may remain under pressure.
• Accounts-receivable and working-capital risk: At the end of 2025, the company’s accounts-receivable book balance was RMB 9.519 billion, equivalent to approximately 21.83% of 2025 revenue. Approximately 93.70% was due within one year. The large scale of pharmaceutical distribution and settlement cycles with hospitals and channels may create sustained working-capital needs. Slower collections could increase bad-debt and cash-flow pressure.
• Low-margin pharmaceutical distribution and customer-collection risk: Pharmaceutical distribution generated revenue of RMB 28.697 billion in 2025 and accounted for a high proportion of total company revenue, but primarily provides scale, channels and cash flow. The segment is affected by hospital collection cycles, terminal cost controls and margin compression across distribution links. Revenue growth may not translate into corresponding profit growth.
• Share-price and fund-flow weakness: The closing price was RMB 26.26 on September 11, 2026, below major moving averages and close to the 52-week low of RMB 25.63. MACD was in negative territory, while main funds recorded aggregate net outflows of approximately RMB 169 million over the preceding five trading days and margin funds showed net repayments. If the RMB 25.6–25.9 area breaks on high volume, short-term market volatility and valuation pressure may increase further.

8. Conclusion and Outlook

Huadong Medicine’s medium-term growth thesis depends mainly on continued volume growth for innovative and specialty drugs at Sino-American Huadong, a higher contribution from pharmaceutical manufacturing, and the subsequent commercialization of ADC, peptide, GLP-1, xRNA and industrial-microbiology projects. Sino-American Huadong and industrial microbiology maintained relatively strong growth in the first half of 2026, while net cash flow from operating activities was RMB 2.499 billion, indicating resilience in the core manufacturing businesses and overall operations. The company also implemented a cash dividend of RMB 3.50 per 10 shares, totaling approximately RMB 614 million.

Whether the medical-aesthetics business can stop its decline and stabilize is an important variable affecting earnings elasticity and valuation recovery. MaiLi Precise and other products have made progress in registration or certification, but the company has stated that their short-term financial impact is limited. Future sales will depend on industry demand, channel coverage, the competitive landscape and terminal pricing systems. Institutional earnings expectations vary considerably. The forecast range for 2026 net profit attributable to shareholders is approximately RMB 3.427–4.261 billion, reflecting differing views on the pace of medical-aesthetics recovery, the absorption of centralized-procurement effects and the volume ramp-up of innovative products.

From an operating and market-performance perspective, the company remains in a phase of business-structure adjustment. Pharmaceutical distribution is large in scale but has low margins, and the book balance of accounts receivable represented approximately 21.83% of 2025 revenue. Pharmaceutical manufacturing growth has been relatively stable, but centralized procurement, reimbursement access and commercialization of R&D remain sources of pressure. Medical aesthetics and overseas operations have not yet fully recovered. The share price is currently in a low-level consolidation or bottom-finding phase. Future improvement in fundamental expectations will need to be assessed by considering changes in medical-aesthetics revenue, the market conversion of non-selected centralized-procurement products, innovative-drug clinical progress and capital support.

Data Sources

• https://cs.cnpharm.com/upload/resources/file/2026/04/24/187957.pdf
• Huadong Medicine Co., Ltd. 2025 Annual Report Summary | Shanghai Securities Journal
• Huadong Medicine (000963)_Company Announcements_Huadong Medicine: 2024 Annual Report_Sina Finance_Sina.com
• Huadong Medicine Co., Ltd. 2023 Annual Report Summary | Shanghai Securities Journal
• Huadong Medicine Co., Ltd. 2024 Annual Report Summary
• Huadong Medicine Co., Ltd. 2025 Annual Report
• Hengrui Medicine (600276)_Company Announcements_Hengrui Medicine: 2025 Annual Report Summary_Sina Finance_Sina.com
• Sichuan Kelun Pharmaceutical Co., Ltd. 2025 Annual Report
• Shanghai Pharmaceuticals Holding Co., Ltd. 2025 Annual Report
• Imeik Technology Development Co., Ltd.　　　　　　　　　　　　　　　　　　　　　　　　　2025 Annual Report
• Huadong Medicine (000963)_Company Announcements_Huadong Medicine: 2026 Semiannual Report_Sina Finance_Sina.com
• Huadong Medicine (000963): Centralized-Procurement Pressure Emerges; Innovation Drives Transformation_Sina Finance_Sina.com
• Huadong Medicine (000963)_Company Announcements_Huadong Medicine: 2025 Annual Report_Sina Finance_Sina.com
• Huadong Medicine (000963): Profit Meets Expectations; Innovative Businesses and Industrial Microbiology Perform Strongly_Sina Finance_Sina.com
• Huadong Medicine (000963) Earnings Forecast_F10_Tonghuashun Financial Services
• Huadong Medicine (000963) Earnings Forecast_F10_Tonghuashun Financial Services
• Huadong Medicine (000963): Innovation Drives Growth in 1H26_Sina Finance_Sina.com
• Huadong Medicine (000963) Analyst Consensus Estimates_Market Sentiment_Investing.com
• Huadong Medicine (000963) P/E | Valuation | Fundamentals - LiXinger
• Huadong Medicine (000963) Historical Stock Data: Historical Quotes, Prices and Charts_Investing.com
• Huadong Medicine 000963 Intraday Chart, 000963 K-Line Chart, Real-Time Quotes and Trading Data_DDX Query
• Huadong Medicine (000963) - Historical Trading Data | Dabanke
• Chiyu Banking Corporation
• Huadong Medicine (000963) Stock Trend and Technical Analysis_Future Forecast_Buy/Sell Recommendations_Investing.com
• Huadong Medicine (000963) Trend Analysis | Pattern Not Hit | Dingcrab Market Companion
• Huadong Medicine (000963) Stock Analysis_Niucha Stock Diagnosis_Tonghuashun Finance
• Huadong Medicine (000963) Latest Developments_F10_Tonghuashun Financial Services

This report was automatically retrieved, compiled and generated by AI based on publicly available information. Information is current as of the September 11, 2026 close; shareholder and institutional holding data are as of June 30, 2026 and subject to a quarterly lag. Timing differences may exist. Specific data should be based on the company’s official announcements and authoritative data terminals. This report is for information and research reference only and does not constitute investment advice. Investors should make independent judgments and bear their own investment risks.